Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of genetic polymorphisms in CYP3A4, CYP3A5, and m-TOR on everolimus blood exposure and clinical outcomes in cancer patients.

The pharmacogenomics journal - 1 Oct 2020

Bonnet Stéphanie, Falkowski Sabrina, Deppenweiler Marine, Monchaud Caroline, Arnion Hélène, Picard Nicolas, Woillard Jean-Baptiste

Abstract excerpt

Genetic variations in CYP3A4, CYP3A5, and m-TOR could contribute to interpatient variability regarding m-TOR inhibitors pharmacokinetics or cellular effects. The purpose of this study was to evaluate the influence of selected candidate variations in these genes on everolimus pharmacokinetics, efficacy, and toxicity in cancer patients. Thirty-four patients receiving everolimus for breast (n = 22) or renal (n = 10)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Monitoring

Share to Everolimus

Share to Pharmacogenetics

Share to Pharmacogenomic Variants

Share to Progression-Free Survival

Share to TOR Serine-Threonine Kinases

Source

Identifiers

PMID: 32015456
DOI: 10.1038/s41397-020-0152-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of genetic polymorphisms in CYP3A4, CYP3A5, and m-TOR on everolimus blood exposure and clinical outcomes in cancer patients.PMID 32015456Read ↗

Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.Semantic proximity Read ↗

The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients.Semantic proximity Read ↗

Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer.Semantic proximity Read ↗

Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer.Semantic proximity Read ↗

Model‐Based Quantification of Impact of Genetic Polymorphisms and Co‐Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast CancerSemantic proximity Read ↗

Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial.Semantic proximity Read ↗

Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment.Semantic proximity Read ↗

Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma.Semantic proximity Read ↗

Meta-Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure.Semantic proximity Read ↗

Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity.Semantic proximity Read ↗

Pilot Study on the Impact of Polymorphisms Linked to Multi-Kinase Inhibitor Metabolism on Lenvatinib Side Effects in Patients with Advanced Thyroid Cancer.Semantic proximity Read ↗

CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.